Beyond Organs: Genetics Now Guide Cancer Therapy

Precision oncology marks a significant shift in cancer care, moving beyond treating based on tumor origin to analyzing specific genetic mutations like EGFR and ALK. This personalized approach aims to improve patient outcomes by selecting therapies that target the tumor's unique biology. The field is rapidly advancing due to decreasing genome sequencing costs and AI-driven discoveries.

India is experiencing a surge in cancer cases, with projections indicating nearly 25 lakh by 2045. To support this transition, India is building crucial infrastructure. The Bharat Cancer Genome Atlas was launched in February 2025, and a National Biobank was established in July 2025 in New Delhi to foster personalized treatment research.

The global precision oncology market was valued at $115 billion in 2024 and is expected to grow to $200 billion by 2029. India's market is also expanding, projected to reach $8.9 billion by 2030. Companies like Metropolis Healthcare and Syngene International are strategically positioning themselves within this evolving healthcare landscape.

Metropolis Healthcare is enhancing its diagnostic capabilities through acquisitions, focusing on oncology-specific testing. Syngene International, a leading CRDMO, is enabling the development of next-generation cancer therapies by offering specialized research and manufacturing services, including a growing focus on antibody-drug conjugates (ADCs).